Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Cobroxin OTC pain reliever is now available online

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Studies show that physiotherapy can help relieve symptoms of prostatitis

Prostatitis is no picnic. It is a urological condition which causes infection or inflammation of the prostate gland. It is a fairly common health concern, especially for men under 50 and can seriously affect quality of life including sexuality and intimate relationships. However, new research regarding the benefits of physiotherapy in treating prostititis is promising.

14 Oct 2009

National Vaccine Information Center to launch a research fundraising campaign

At the Oct. 2-4, 2009 Fourth International Public Conference on Vaccination sponsored by the non-profit National Vaccine Information Center in Reston, VA, 700 citizens from 44 states and 11 nations raised more than $100,000 to launch an international scientific research fundraising campaign to investigate health differences between vaccinated and unvaccinated children and identify those at risk for suffering vaccine injury.

14 Oct 2009

Laser Spine Institute opens medical consultation facilities in Beverly Hills and Fort Lauderdale

After helping thousands of patients get their lives back through minimally invasive endoscopic spine surgery at facilities in Tampa, Scottsdale, and soon in Philadelphia, the Laser Spine Institute (LSI) announces the opening of their newest medical consultation facilities -- in Beverly Hills, Ca., and Fort Lauderdale, Fla., in October -- which aim to meet the growing demand for LSI's spinal procedures and provide greater convenience for local patients.

14 Oct 2009

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Legendary coach helps raise awareness on osteoarthritis

After leading the U.S. men’s basketball team to Olympic gold last year and two weeks before the start of his 30th season as head coach of Duke University’s men’s basketball team, Mike Krzyzewski (Coach K), 61, is teaming up with the Arthritis Foundation to help raise awareness of the disease that nearly ended his coaching career 10 years ago.

13 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

U.S. women with RA feel less self-confident in their sex-life, reveals survey

A new survey of U.S. women living with rheumatoid arthritis (RA) published today reveals that RA has a clear emotional impact on people living with the disease, with loss of self-confidence seen in their sex lives, in the workplace, and in their social lives.

12 Oct 2009

Doctors and scientists form national pain research centre

An expert network of doctors and research scientists is forming the world's first national centre for research into understanding pain in arthritis. Backed by medical research charity the Arthritis Research Campaign and The University of Nottingham, it will aim to improve treatments for arthritis - the most common cause of chronic pain - which affects more than ten million people in the UK.

12 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

WCMC-Q program highlights the importance of mental health to overall physical health

Mental health professionals from Weill Cornell Medical College in Qatar and the community highlighted the importance of mental health to overall physical health during a presentation Sunday as part of the medical college's recognition of World Mental Health Day.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Cobroxin OTC pain reliever is now available online

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Studies show that physiotherapy can help relieve symptoms of prostatitis

National Vaccine Information Center to launch a research fundraising campaign

Laser Spine Institute opens medical consultation facilities in Beverly Hills and Fort Lauderdale

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Johnson & Johnson announces financial results for the third quarter of 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Legendary coach helps raise awareness on osteoarthritis

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

U.S. women with RA feel less self-confident in their sex-life, reveals survey

Doctors and scientists form national pain research centre

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

WCMC-Q program highlights the importance of mental health to overall physical health

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in